<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01644825</url>
  </required_header>
  <id_info>
    <org_study_id>MITO-11</org_study_id>
    <secondary_id>2009-016151-21</secondary_id>
    <nct_id>NCT01644825</nct_id>
  </id_info>
  <brief_title>Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian Cancer</brief_title>
  <acronym>MITO-11</acronym>
  <official_title>MITO-11: A Randomized Multicentre Phase II Trial With Pazopanib and Weekly Paclitaxel vs Weekly Paclitaxel in Platinum Resistant or Refractory Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and activity of adding pazopanib to&#xD;
      weekly chemotherapy with paclitaxel for patients with ovarian cancer that is resistant or&#xD;
      refractory to treatment with platinum based therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2010</start_date>
  <completion_date type="Actual">December 29, 2015</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>6 months from randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of patients with objective response</measure>
    <time_frame>at 2 months and 4 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>worst grade toxicity per patient</measure>
    <time_frame>at end of each 28 day cycle of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>one year from randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>paclitaxel and pazopanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>paclitaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>80 mg/m2 IV days 1, 8, 15 every 28 days</description>
    <arm_group_label>paclitaxel</arm_group_label>
    <arm_group_label>paclitaxel and pazopanib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pazopanib</intervention_name>
    <description>orally, 800 mg orally daily</description>
    <arm_group_label>paclitaxel and pazopanib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cytologic / histologic diagnosis of stage IC-IV ovarian cancer&#xD;
&#xD;
          -  Disease progressed during first line chemotherapy or disease relapsed within 6 months&#xD;
             after the last platinum treatment&#xD;
&#xD;
          -  Disease evaluable by RECIST or Ca 125 GCIG criteria&#xD;
&#xD;
          -  No residual peripheral neurotoxicity from previous chemotherapy treatment&#xD;
&#xD;
          -  PS 0-1&#xD;
&#xD;
          -  Aged at least 18 and not greater than 75 years.&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
          -  Able to swallow and retain oral medication&#xD;
&#xD;
          -  Written informed consent prior to performance of study specific procedures or&#xD;
             assessments&#xD;
&#xD;
          -  Ability and willingness to comply with treatment and follow up assessments and&#xD;
             procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        · • Previous or concomitant malignant neoplasia (not including basocellular or&#xD;
        spinocellular skin carcinoma or in-situ carcinoma of the uterine cervix, provided they are&#xD;
        being adequately treated)&#xD;
&#xD;
          -  Previous treatment with weekly paclitaxel&#xD;
&#xD;
          -  More than 2 previous chemotherapy treatments&#xD;
&#xD;
          -  Serious heart disease, including heart failure, atrioventricular block of any degree,&#xD;
             serious arrhythmia or history of any one or more of the following cardiovascular&#xD;
             conditions within the past 6 months: cardiac angioplasty or stenting, myocardial&#xD;
             infarction, unstable angina, symptomatic peripheral vascular disease, coronary artery&#xD;
             by-pass graft surgery, class II, III or IV congestive heart failure as defined by the&#xD;
             New York Heart Association (NYHA)&#xD;
&#xD;
          -  Hemoglobin &lt; 9 g/dL, neutrophils &lt; 1500/mm3, platelets &lt; 100000/mm3&#xD;
&#xD;
          -  Impairment of renal function (patients should have 2 functioning kidneys): creatinine&#xD;
             1.5 times the upper normal limit - UNL; calculated creatinine clearance &lt; 50 mL/min;&#xD;
             urine protein to creatinine ratio &gt; or = 1: then, a 24-hour urine protein must be&#xD;
             assessed and subject must have a 24-hour urine protein value &lt;1gr to be eligible&#xD;
&#xD;
          -  Impairment of liver function (SGOT or SGPT &gt; or = 2.5 UNL, alkaline phosphatase &gt; 2.5&#xD;
             ULN, total bilirubin &gt; 1.5 times the UNL)&#xD;
&#xD;
          -  Prothrombin time (PT) or international normalized ratio (INR) or activated partial&#xD;
             thromboplastin time (PTT) &gt; 1.2 times the UNL&#xD;
&#xD;
          -  Pregnancy, breast feeding, or inadequate contraception&#xD;
&#xD;
          -  Unable to discontinue prohibited medications (see protocol section 6.7)&#xD;
&#xD;
          -  Clinically significant gastrointestinal abnormalities which might interfere with oral&#xD;
             dosing, including but not limited to malabsorption syndrome, major resection of the&#xD;
             stomach or small bowel that could affect drug absorption, active peptic ulcer disease,&#xD;
             inflammatory bowel disease, ulcerative colitis, other gastrointestinal conditions with&#xD;
             increased risk of perforation, history of abdominal fistula, gastrointestinal&#xD;
             perforation, or intra-abdominal abscess within 28 days prior to beginning study&#xD;
             treatment, signs or symptoms of GI obstruction&#xD;
&#xD;
          -  Any unstable or serious concurrent condition&#xD;
&#xD;
          -  Prolongation of corrected QT interval (QTc) &gt;480 ms&#xD;
&#xD;
          -  History of cerebrovascular accident, pulmonary embolism or untreated deep venous&#xD;
             thrombosis (DVT) within the past 6 months&#xD;
&#xD;
          -  Macroscopic hematuria&#xD;
&#xD;
          -  Major surgery or trauma within 30 days&#xD;
&#xD;
          -  Hypertension uncontrolled with adequate therapy (systolic blood pressure (BP) of &gt; or&#xD;
             = 140mmHg, or diastolic BP of &gt; or = 90mmHg)&#xD;
&#xD;
          -  Any ongoing toxicity from prior anti-cancer therapy that is &gt;Grade 1 and/or that is&#xD;
             progressing in severity&#xD;
&#xD;
          -  Present or suspected haemorrhagic syndromes&#xD;
&#xD;
          -  Patients' inability to access the centre due to area of residence&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandro Pignata, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Perrone, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ciro Gallo, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Campania &quot;Luigi Vanvitelli&quot;</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Osp. Regionale Mulli</name>
      <address>
        <city>Acquaviva delle Fonti</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San donato</name>
      <address>
        <city>Arezzo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. G. Rummo</name>
      <address>
        <city>Benevento</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Bellaria</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Senatore Antonio Perrino</name>
      <address>
        <city>Brindisi</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Garibaldi Nesimadi Catania</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile di Faenza</name>
      <address>
        <city>Faenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Arcispedale Sant'Anna di Ferrara</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Fabrizio Spaziani della ASL di Frosinone</name>
      <address>
        <city>Frosinone</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Umbero I</name>
      <address>
        <city>Lugo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Univeristaria Policlinico</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori , Oncologia Medica - Dipartimento Uro-Ginecologico</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seconda Universita di Napoli</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Silvestrini</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Maria delle Croci AUSL di Ravenna</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Bainchi Melacrino Morelli Osp. Riuniti</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale degli Infermi, P.O. Ospedale Civile</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Gemelli Università Cattolica del Sacro Cuore</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Pignata S, Lorusso D, Scambia G, Sambataro D, Tamberi S, Cinieri S, Mosconi AM, Orditura M, Brandes AA, Arcangeli V, Panici PB, Pisano C, Cecere SC, Di Napoli M, Raspagliesi F, Maltese G, Salutari V, Ricci C, Daniele G, Piccirillo MC, Di Maio M, Gallo C, Perrone F; MITO 11 investigators. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncol. 2015 May;16(5):561-8. doi: 10.1016/S1470-2045(15)70115-4. Epub 2015 Apr 14.</citation>
    <PMID>25882986</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>July 17, 2012</study_first_submitted>
  <study_first_submitted_qc>July 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2012</study_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>platinum resistant</keyword>
  <keyword>platinum refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

